Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 healthcare headlines for February 16 - 23, 2025:
1. Sotagliflozin Cuts MACE Risk By 23% in Patients with Type 2 Diabetes, CKD
Dual SGLT1/2 inhibition with sotagliflozin significantly reduced both heart attacks and stroke in a prespecified secondary analysis of the SCORED trial.
2. Nebokitug (CM-101) Gets FDA Runway for PSC Approval
Chemomab completed an end-of-phase 2 meeting with the FDA and has aligned on the design of a phase 3 registration study for nebokitug (CM-101) in PSC.
3. FDA Clears IND Application for Zabalafin Hydrogel Treatment of Atopic Dermatitis
Alpyn’s Investigational New Drug application’s clearance by the FDA for the new Zabalafin Hydrogel for atopic dermatitis follows positive phase 2a clinical findings.
4. Expert Panel Develops Consensus Definition, Clinical Tool for Anaphylaxis Care
A 46-member expert panel created a consensus anaphylaxis definition, overview, and clinical tool to aid clinicians in recognition and management across settings.
5. FDA Announces End to Shortage of Semaglutide Products (Ozempic, Wegovy)
The US supply of semaglutide and semaglutide 2.4 mg now meets or exceeds current and projected demand, ending the long-running shortages of these blockbuster drugs.
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 healthcare headlines for February 16 - 23, 2025:
1. Sotagliflozin Cuts MACE Risk By 23% in Patients with Type 2 Diabetes, CKD
Dual SGLT1/2 inhibition with sotagliflozin significantly reduced both heart attacks and stroke in a prespecified secondary analysis of the SCORED trial.
2. Nebokitug (CM-101) Gets FDA Runway for PSC Approval
Chemomab completed an end-of-phase 2 meeting with the FDA and has aligned on the design of a phase 3 registration study for nebokitug (CM-101) in PSC.
3. FDA Clears IND Application for Zabalafin Hydrogel Treatment of Atopic Dermatitis
Alpyn’s Investigational New Drug application’s clearance by the FDA for the new Zabalafin Hydrogel for atopic dermatitis follows positive phase 2a clinical findings.
4. Expert Panel Develops Consensus Definition, Clinical Tool for Anaphylaxis Care
A 46-member expert panel created a consensus anaphylaxis definition, overview, and clinical tool to aid clinicians in recognition and management across settings.
5. FDA Announces End to Shortage of Semaglutide Products (Ozempic, Wegovy)
The US supply of semaglutide and semaglutide 2.4 mg now meets or exceeds current and projected demand, ending the long-running shortages of these blockbuster drugs.